Drug Trial News

RSS

HonorHealth study shows major breakthrough in treating structural shock

An 8-year HonorHealth Research Institute clinical trial, using non-surgical techniques, showed 86% of patients with a type of usually fatal low blood pressure known as 'structural shock' survived at least 3 months, while 73% survived at least 6 months, according to a study presented here at a major heart convention.

27 Jun 2025

Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT06414460) to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.

27 Jun 2025

Common autoimmune drug shown to help patients with giant cell arteritis

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of Medicine at the University of Pennsylvania published in the New England Journal of Medicine.

25 Jun 2025

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain imaging revealed that tirzepatide also lowered neural responses to high-fat, high-sugar food cues, offering mechanistic insight into its potent weight-loss effects.

25 Jun 2025

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in adults with obesity, with or without diabetes, in a phase 2 randomized trial. The drug demonstrated an acceptable safety profile and supports further study in phase 3 trials.

24 Jun 2025

ADC189 shows promise as a single-dose treatment for influenza

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality.

24 Jun 2025

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

23 Jun 2025

Genetically engineered skin grafts help heal chronic wounds in patients with epidermolysis bullosa

Skin grafts genetically engineered from a patient's own cells can heal persistent wounds in people with an extremely painful dermatologic disease, a Stanford Medicine-led clinical trial has shown.

23 Jun 2025

Cagrilintide and semaglutide together drive record weight loss in global trial

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful weight loss in adults with obesity but no diabetes. The combination outperformed either drug alone and improved multiple cardiometabolic health markers.

23 Jun 2025

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

Once-weekly amycretin, a novel peptide activating GLP-1, amylin, and calcitonin receptors, produced rapid, substantial, and sustained weight loss in adults with overweight or obesity during a phase 1b/2a trial. The treatment was generally well tolerated, with mostly mild to moderate gastrointestinal side effects, supporting further investigation in larger, longer studies.

23 Jun 2025

BMJ investigation raises new concerns over ticagrelor approval trials

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.

21 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

New clinical trial tests non-invasive method to protect hearts during chemotherapy

A simple intervention, similar to the tension applied to the arm during a blood pressure reading, is being tested in a Phase II clinical trial to see if it can help cancer patients treated with common chemotherapy drugs, called anthracyclines, avoid heart failure.

20 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

A clinical trial involving adolescents with type 1 diabetes (T1D) has found a combination therapy may reduce chronic kidney disease and improve health outcomes.

17 Jun 2025

First patient treated in international clinical trial for rare muscle-weakness disease

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease known as Myasthenia Gravis.

16 Jun 2025

Two existing medications work effectively together in treating alcohol use disorder

Two existing medications - one used for smoking cessation and the other for depression - appear to work effectively together in treating alcohol use disorder.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025

Empagliflozin preserves kidney function in heart attack patients

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease.

13 Jun 2025

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

13 Jun 2025

1
2
3
4
...
1152
Next

Drug Trial News

HonorHealth study shows major breakthrough in treating structural shock

Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412

Common autoimmune drug shown to help patients with giant cell arteritis

Tirzepatide rewires appetite and slashes calorie intake in new obesity trial

Once-monthly obesity injection shows double-digit weight loss in major clinical trial

ADC189 shows promise as a single-dose treatment for influenza

Clinical trial finds new benefits of semaglutide for adults with type 1 diabetes

Genetically engineered skin grafts help heal chronic wounds in patients with epidermolysis bullosa

Cagrilintide and semaglutide together drive record weight loss in global trial

Amycretin delivers unprecedented weight loss in early trial for obesity treatment

BMJ investigation raises new concerns over ticagrelor approval trials

Diabetes medication shows promise in cutting migraine days by more than half

New clinical trial tests non-invasive method to protect hearts during chemotherapy

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

Combination therapy may improve health outcomes in adolescents with type 1 diabetes

First patient treated in international clinical trial for rare muscle-weakness disease

Two existing medications work effectively together in treating alcohol use disorder

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Empagliflozin preserves kidney function in heart attack patients

New drug combination shows high remission rates in acute myeloid leukemia

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News